SCHEMBL4929562

SCHEMBL4929562

CN1CCN(c2ccc(-n3ncc4c(Nc5ccccc5Cl)ncnc43)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.58
TP53 P04637 7/20 0.57
LMNA P02545 7/20 0.57
GAA P10253 4/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
HTT P42858 4/20 0.56
HSD17B10 Q99714 4/20 0.56
TSHR P16473 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPSR1 Q6W5P4 2/20 0.52
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
PIP4K2A P48426 1/20 0.50
MAPK1 P28482 1/20 0.49
CCNK O75909 1/20 0.48
CCNA2 P20248 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931187 0.91 MAPT (0.51) MAPTTP53LMNAGAANPC1
SCHEMBL4928475 0.91 MAPT (0.51) MAPTTP53LMNAGAANPC1
SCHEMBL4925481 0.88 TP53 (0.74) MAPTTP53LMNAGAANPC1
SCHEMBL4931138 0.87 MAPT (0.56) MAPTTP53LMNAGAANPC1
SCHEMBL4924462 0.85 LMNA (0.69) MAPTTP53LMNAGAANPC1
SCHEMBL4927597 0.83 MAPT (0.51) MAPTTP53LMNAGAANPC1
SCHEMBL4927701 0.83 MAPT (0.55) MAPTTP53LMNAGAANPC1
SCHEMBL4939562 0.82 MAPT (0.55) MAPTTP53LMNAGAANPC1
SCHEMBL4924582 0.82 TP53 (0.59) MAPTTP53LMNAGAANPC1
SCHEMBL4921977 0.82 MAPT (0.52) MAPTTP53LMNAGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US claimed
EP-1812441-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2007-08-01 EP claimed
WO-2006050946-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-05-18 WO claimed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 MAPT 1638/4885TP53 849/4885LMNA 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.